Abstract: A composition is disclosed which comprises a solution in a pharmaceutically acceptable carrier of an immune serum globulin, said solution having an ionic strength and a pH to maintain the monomer content and the actual and latent anticomplement activity of the immune serum globulin such that the composition is intravenously injectable. Novel methods are disclosed for preparing the above composition.

Abstract: Film material for use in sterilized medical solution containers such as blood bags or I.V. bags, comprising 30-90% linear low density polyethylene (LLDPE) and 10-70% styrene-ethylene-butylene-styrene (SEBS). The particular LLDPE and SEBS materials are selected from among known LLDPE and SEBS materials according to density, in the case of LLDPE, and styrene/rubber ratio and composition in the case of SEBS. Up to 10% of an optional third component such as high melt index LLDPE or polypropylene may be added as a processing aid. Material having greater than 50% LLDPE is particularly well suited for medical solution container application.

Abstract: There is disclosed an oral pharmaceutical composition for therapeutic use comprising a therapeutically effective amount of orally administerable immune globulin in a pharmaceutically acceptable carrier.

Abstract: Novel antihemophilic factor concentrates and process for making the same are disclosed. An aqueous solution of anithemophilic factor proteins is obtained, preferably by solubilizing antihemophilic factor proteins from blood plasma cryoprecipitate in water. The aqueous solution is purified to remove unwanted protein, for example, by mixing the aqueous solution with aluminum hydroxide. Then, the aqueous solution is ultrafiltered to concentrate it, mixed with buffer and saline and adjusted to an acid pH, and freeze-dried.

Abstract: Novel compositions containing fibronectin and methods of isolating these compositions and fibronectin itself from blood plasma are disclosed.

Abstract: Fraction IV, a discard fraction of the Cohn fractionation scheme, may be used as a supplement in cell growth media if the Fraction IV is rendered substantially free of components within the molecular weight range 2.5.times.10.sup.5 -1.0.times.10.sup.10, which components inhibit cell growth.

Abstract: A lectin-containing, water-insoluble gel matrix with a glycoprotein reversibly bound thereto can be used for fractionating a polysaccharidic substance capable of being separated into components of differing activity by virtue of differing affinity for the glycoprotein. In this manner, heparin can be fractionated into high activity and low activity components.

Abstract: A broad spectrum anthelmintic composition useful for eliminating nematodes and cestodes from carnivores. Composition comprises anthelmintically effective amounts of compounds which act systemically and via direct contact in carnivore gut, the compounds being carried in a vehicle which provides simultaneous systemic and direct contact availability of the compounds. Preferred composition comprises febantel and praziquantel compounds in an aqueous paste-like formulation.

Abstract: A lectin-containing, water-insoluble gel matrix with a glycoprotein reversibly bound thereto can be used for fractionating a polysaccharidic substance capable of being separated into components of differing activity by virtue of differing affinity for the glycoprotein. In this manner, heparin can be fractionated into high activity and low activity components.

Abstract: A complex of antithrombin and high activity heparin is provided for use as a potent anticoagulant for humans. The complex is prepared by reversibly immobilizing it on a lectin-containing, water-insoluble gel matrix and then removing it from the matrix.

Abstract: A novel casting or splinting package is disclosed wherein a sheet comprising a textile substrate impregnated or coated with a water-curable resin system is non-sealably confined between a sheet of resilient, non-water-absorptive material and a sheet of flexible, non-water-absorptive material. The assembled sheets are enclosed in a porous envelope. In use, the casting or splinting package is immersed in water, squeezed to remove excess water, and then applied to and formed about the body part to be immobilized or supported whereupon the package becomes rigid.

Abstract: Compositions containing thermally sensitive, therapeutically active proteins are pasteurized without substantial loss of therapeutic activity by mixing the protein composition with a pasteurization-stabilizing amount of a polyol prior to pasteurization. Pasteurized compositions containing therapeutically active proteins, which have heretofore been unattainable, can be prepared by the method of the invention.

Abstract: There is disclosed a needle assembly comprising a needle, a needle-retaining portion, a removable needle protector portion, and a resilient member for removing liquid from the surface of the needle which is disposed around the needle rearward of its point. The liquid removing member has a needle-accommodating opening with a diameter approximately that of the outside diameter of the needle. The member is contained within the needle protector portion and removable from the needle with the removal of the needle protector portion from the assembly. Also disclosed are blood bag systems comprising a donor bag and the aforementioned needle assembly.

Abstract: Injection site device comprising an elastomeric plug closing a fluid entry port and held in a compression fit by means of an open overcap bonded to the outer surfaces of the entry port.

Abstract: A ready-to-use liquid elemental diet comprising a nutritionally acceptable combination of carbohydrate, amino acid, and lipid components, the combination having a pH ranging from about 3.0 to 4.4, being non-browning at elevated temperatures, and including, as the lipid component, a stable emulsion comprising a lipid source, an emulsifier and a starch modified with succinic anhydride in quantities sufficient to maintain emulsion stability in the pH range of about 3.0 to 4.4.

Abstract: There is disclosed a pharmaceutical composition for therapeutic use comprising an immune globulin and fibronectin in amounts sufficient to produce an opsonic activity in the composition that is greater than the additive opsonic activity of the individual agents or in amounts sufficient to produce a phagocytosis of infectious agents greater than the additive effect from fibronectin and immune globulin alone.

Abstract: This disclosure pertains to a concentrate for controlling bleeding in hemophilia, free of thrombin, heparin, thromboplastin activity, anticomplement activity, depressor activity, and activated Factor X, and containing coagulation Factors II, VII, IX, and X in non-activated form and containing no greater amounts of calcium-activated factors and Factor VIII Inhibitor Bypassing Activity substance than that found in concentrates of Factor II, VII, IX, and XI that have not been treated, respectively, with calcium or a material which would produce a Factor VIII Inhibitor Bypassing Activity substance in such concentrates and having a specific activity of at least about 1.5 Factor IX units per milligram of total protein and a Factor IX:Factor VII ratio of at least about 6:1, a Factor IX:Factor II ratio of about 1:1 to 2:1, and a Factor IX:NAPTT ratio of at least about 5:1 on a Units per milliliter basis, a Factor II Specific Activity of about 1.0-4.

Abstract: A closure for containers which is inexpensively and easily manufactured and is readily removeable in whole or in part to gain access to contents in the container. The closure comprises a generally flat cap member sealed at its periphery to the mouth of the container. An upstanding tubular member on the surface of the cap is partially surrounded by a score line in the cap and the score line preferably continues all around the cap near its periphery. The tubular member preferably has rigidifying means in its closed top and side walls which can be readily flexed inwardly so that the tubular member can be firmly grasped and pulled to readily initiate a rupture in the score line at a stress-concentrating focal point on that portion of the score line adjacent the tubular member. The cap can then be easily removed by continued pulling of the tubular member.

Abstract: Stable plasma protein fractions (PPF) substantially free of vasodepressant amounts of acetate ions are disclosed. Solutions of the disclosed PPF are suitable for intravenous administration to patients without deleterious vasodepressor effects. Methods are also described for preparing the aforementioned PPF.

Abstract: Blood-coagulation-promoting products substantially free of thrombin are prepared from human blood plasma by contacting a human blood plasma fraction containing coagulation Factors II, VII, IX and X with an anion exchanger to adsorb the coagulation Factors, which are subsequently eluted from the anion exchanger. The eluate is treated to generate a substance having Factor VIII Inhibitor Bypassing Activity and being substantially free of thrombin, and activated Factor X.